BioNexus Gene Lab Corp (BGLC) AI Stock Analysis
BGLC AI stock analysis summary
AI ResearchBioNexus Gene Lab Corp (BGLC) sells chemical raw materials and provides genomic screening services in Southeast Asia. The company generated $3.1M in trailing twelve months revenue, with net losses accelerating to -$3.0M in FY2025. While it maintains net cash of $3.3M as of June 30, 2026, revenue fell 96.6% year-over-year in its latest quarter.
- Market cap
- $3.5M
- Revenue (TTM)
- $3.1M
- P/E
- —
- 1Y return
- -76.7% S&P 500 16.8%
- Avg. target
- —
Bull case
- BioNexus Gene Lab Corp holds a net cash balance of $3.3M with minimal total debt of $198,585 as of June 30, 2026.
- The balance sheet maintains strong short-term liquidity, underscored by a current ratio of 6.08 as of June 30, 2026.
- The stock trades at a price-to-book ratio of 0.6x, below its book value of $7.8M in shareholders' equity.
Bear case
- Quarterly revenue fell 96.6% year-over-year in the latest quarter ended June 30, 2026.
- Free cash flow has remained negative over three straight fiscal years, finishing at -$1.9M in FY2025.
- Operating margin for the trailing twelve months plunged to -398.7% alongside a profit margin of -82.4%.
What BioNexus Gene Lab does
BioNexus Gene Lab Corp. focuses on the sale of chemical raw materials for industrial, medical, appliance, aero, automotive, mechanical, and electronic manufacturing across Malaysia, Indonesia, Vietnam, and other Southeast Asian countries. It operates through three segments: Trading of Industrial Chemicals, Provision for Genomic Screening Services, and Investment Holding. Its chemical offerings include polyester resins such as SHCP 268, 9509 for marine boats and water slides, and 2802 for the pultrusion process. These materials are used to make handrails, clean room panels, bench tops, and vehicle components. Additionally, the company develops non-invasive liquid biopsy tests for early biomarker detection.
Growth and profitability
Revenue has steadily dropped from $13.4M in FY2021 to $10.9M in FY2022, $9.8M in FY2023, $9.5M in FY2024, and $7.4M in FY2025, delivering a 5-year revenue CAGR of -8.2%. Profitability deteriorated alongside top-line contraction, shifting from net income of $751,571 in FY2021 to net losses of -$2.6M in FY2023, -$1.6M in FY2024, and -$3.0M in FY2025. In FY2025, operating margin was -42.5% and net margin was -40.2%. For the trailing twelve months ended June 30, 2026, revenue stood at $3.1M with an operating margin of -398.7% and a profit margin of -82.4%. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 96.6% year-over-year, while quarterly earnings growth dropped 95.0%.
Balance sheet and cash flow
As of June 30, 2026, BioNexus Gene Lab Corp held $3.5M in cash and short-term investments against total debt of $198,585, resulting in net cash of $3.3M. Total assets were $8.7M and shareholders' equity was $7.8M, supported by a current ratio of 6.08 and a debt-to-equity ratio of 0.03. Operating cash flow was -$1.8M and free cash flow was -$1.9M in FY2025. Capital expenditures totaled $36,971 and dividends paid were $22,112 in FY2025.
Valuation and performance
At a last close of $1.20 on October 16, 2026, BGLC has a market capitalization of $3.5M and an enterprise value of $989,212. It trades at a price-to-sales multiple of 1.1x and an enterprise value-to-revenue of 0.3x, compared to a median price-to-sales of 1.8x for its US-listed Basic Materials peers. Its EV-to-EBITDA stands at 629.5x versus the peer median of 10.5x, and its price-to-book ratio is 0.6x. Over the past year, BGLC stock declined 76.7%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 90.0% compared to an 83.0% gain for SPY.
What analysts expect
No analyst consensus ratings, price targets, or earnings estimates are provided for BGLC. The company's next earnings date is scheduled for November 13, 2026. The stock closed at $1.20 on October 16, 2026, which is 43.0% below its 200-day moving average and sits between its 52-week low of $1.07 and 52-week high of $5.89.
Key risks and what to watch
- Operating cash flow was -$1.8M in FY2025, which threatens to erode cash and short-term investments of $3.5M if burn rates persist.
- The 5-year revenue CAGR of -8.2% reflects structural top-line contraction from $13.4M in FY2021 down to $7.4M in FY2025.
- A beta of 2.20 signals elevated price volatility relative to the broader market, following a 76.7% decline over the past year.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this BGLC AI stock analysis
This page is an AI-written research summary of BioNexus Gene Lab Corp (BGLC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: BGLC income statement, BGLC balance sheet, BGLC key metrics, BGLC chart. See the BGLC stock overview for the latest quote and news.
BGLC AI stock analysis FAQ
What is BGLC's net cash position?
As of June 30, 2026, BGLC held $3.5M in cash and short-term investments and $198,585 in total debt, giving it net cash of $3.3M.
How fast is BGLC growing revenue?
Revenue has contracted from $13.4M in FY2021 to $7.4M in FY2025, representing a 5-year revenue CAGR of -8.2%. In the quarter ended June 30, 2026, revenue dropped 96.6% year-over-year.
What is BGLC's valuation compared to peers?
BGLC trades at a price-to-sales multiple of 1.1x, below the 1.8x median for its US-listed Basic Materials peers. However, its EV-to-EBITDA ratio is 629.5x compared to the peer median of 10.5x.
When does BGLC report its next earnings?
The company's next earnings date is scheduled for November 13, 2026.